Your browser is no longer supported. Please, upgrade your browser.
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own1.65% Shs Outstand210.31M Perf Week3.04%
Market Cap969.90M Forward P/E- EPS next Y-0.76 Insider Trans-0.33% Shs Float206.92M Perf Month-21.88%
Income-221.00M PEG- EPS next Q-0.32 Inst Own38.00% Short Float22.37% Perf Quarter-32.34%
Sales6.50M P/S149.22 EPS this Y11.30% Inst Trans0.43% Short Ratio10.78 Perf Half Y-46.81%
Book/sh2.16 P/B2.20 EPS next Y33.10% ROA-38.10% Target Price13.62 Perf Year-50.83%
Cash/sh1.93 P/C2.46 EPS next 5Y- ROE-44.10% 52W Range4.47 - 19.00 Perf YTD-4.81%
Dividend- P/FCF- EPS past 5Y-20.20% ROI-24.90% 52W High-75.00% Beta0.51
Dividend %- Quick Ratio9.50 Sales past 5Y-28.80% Gross Margin- 52W Low6.26% ATR0.32
Employees262 Current Ratio9.50 Sales Q/Q50.00% Oper. Margin- RSI (14)35.16 Volatility5.63% 6.05%
OptionableYes Debt/Eq0.03 EPS Q/Q-360.20% Profit Margin- Rel Volume1.13 Prev Close4.61
ShortableYes LT Debt/Eq0.03 EarningsNov 09 AMC Payout- Avg Volume4.29M Price4.75
Recom2.70 SMA20-10.92% SMA50-23.83% SMA200-37.08% Volume4,839,706 Change3.04%
Dec-29-21Resumed Jefferies Hold $8 → $6
Sep-10-21Downgrade BofA Securities Neutral → Underperform $9 → $8
Jun-24-21Initiated Jefferies Hold $9
Mar-23-21Initiated BofA Securities Neutral $13
Feb-12-21Initiated Oppenheimer Outperform $35
Nov-17-20Downgrade ROTH Capital Neutral → Sell
Nov-10-20Upgrade ROTH Capital Sell → Neutral $8
Sep-28-20Upgrade Maxim Group Hold → Buy $20
Sep-28-20Downgrade Cantor Fitzgerald Overweight → Neutral
Jul-01-20Downgrade ROTH Capital Neutral → Sell $11
Jul-01-20Downgrade Maxim Group Buy → Hold
Jun-29-20Downgrade H.C. Wainwright Buy → Neutral
Jun-26-20Downgrade Stifel Buy → Hold $19 → $24
May-21-20Initiated The Benchmark Company Buy $28
Apr-30-20Downgrade ROTH Capital Buy → Neutral $13
Mar-13-20Downgrade RBC Capital Mkts Outperform → Sector Perform
Mar-13-20Downgrade Piper Sandler Overweight → Neutral
Dec-19-19Initiated ROTH Capital Buy $13
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Jan-11-22 10:00AM  
Dec-30-21 03:49PM  
Dec-21-21 05:21PM  
Dec-19-21 08:33AM  
Dec-15-21 07:12PM  
Dec-14-21 08:00AM  
Dec-03-21 04:15PM  
Dec-02-21 06:30AM  
Nov-30-21 08:00AM  
Nov-26-21 06:04PM  
Nov-21-21 08:04AM  
Nov-17-21 06:54AM  
Nov-16-21 08:00AM  
Nov-15-21 08:00AM  
Nov-12-21 06:22PM  
Nov-10-21 12:30PM  
Nov-09-21 05:25PM  
Nov-05-21 08:00AM  
Nov-03-21 08:00AM  
Nov-02-21 03:02PM  
Nov-01-21 07:41AM  
Oct-27-21 08:00AM  
Oct-26-21 08:00AM  
Oct-21-21 08:00AM  
Oct-20-21 07:51AM  
Oct-13-21 05:51AM  
Oct-12-21 08:00AM  
Oct-11-21 08:00AM  
Oct-06-21 11:15AM  
Sep-29-21 08:00AM  
Sep-24-21 11:20AM  
Sep-22-21 08:00AM  
Sep-10-21 02:42PM  
Sep-08-21 06:06AM  
Sep-03-21 06:00AM  
Sep-01-21 08:00AM  
Aug-26-21 11:50AM  
Aug-25-21 09:12AM  
Aug-20-21 07:39AM  
Aug-17-21 03:08PM  
Aug-12-21 08:41AM  
Aug-10-21 02:22PM  
Aug-09-21 06:05PM  
Aug-05-21 09:49AM  
Aug-04-21 08:00AM  
Aug-02-21 03:01PM  
Jul-26-21 08:00AM  
Jul-22-21 06:20AM  
Jul-18-21 06:36AM  
Jul-15-21 06:06AM  
Jul-14-21 02:07PM  
Jul-12-21 10:05AM  
Jul-08-21 02:14PM  
Jul-05-21 06:06AM  
Jun-30-21 04:12PM  
Jun-21-21 04:51PM  
Jun-17-21 06:00AM  
Jun-16-21 07:28AM  
Jun-10-21 11:46AM  
Jun-09-21 01:19AM  
Jun-08-21 10:34AM  
Jun-07-21 09:07AM  
Jun-06-21 01:15PM  
Jun-03-21 08:00AM  
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon optimized plasmids that have ability to help break the immune system's tolerance of cancerous or infected cells and facilitate cross-strain protection against unmatched and matched pathogen variants. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zoth Lota S.DirectorJan 05Sale5.019614,81525,016Jan 05 04:04 PM
Humeau LaurentChief Scientific OfficerAug 09Sale9.1510,31794,40168,587Aug 11 04:03 PM
KIES PETERCFOJun 09Option Exercise2.1613,75029,700164,538Jun 11 04:24 PM
Shea Jacqueline ElizabethChief Operating OfficerJun 09Sale10.0138,535385,73521,592Jun 11 04:26 PM
Humeau LaurentChief Scientific OfficerJun 09Sale9.0710,31893,58478,904Jun 11 04:25 PM
KIES PETERCFOJun 09Sale10.0133,750337,838130,788Jun 11 04:24 PM
KIES PETERCFOJun 03Sale8.0310,00080,300150,788Jun 04 04:08 PM
Zoth Lota S.DirectorMay 17Sale6.622,04513,53821,887May 17 04:29 PM
Weiner David B.DirectorMay 17Sale6.623,04520,158856,791May 17 04:27 PM
Weiner David B.DirectorApr 21Option Exercise2.4022,50054,000877,719Apr 21 05:03 PM
Weiner David B.DirectorApr 21Sale8.5726,583227,694851,136Apr 21 05:03 PM
KIES PETERCFOApr 21Sale8.5210,00085,200160,788Apr 21 06:00 PM
BENITO SIMON XDirectorApr 16Option Exercise3.562,0007,12053,650Apr 16 05:12 PM
BENITO SIMON XDirectorApr 16Sale8.752,00017,50051,650Apr 16 05:12 PM
Shea Jacqueline ElizabethChief Operating OfficerMar 26Sale8.974,71042,24960,127Mar 26 04:10 PM
BENITO SIMON XDirectorMar 16Option Exercise3.562,0007,12053,650Mar 16 04:55 PM
BENITO SIMON XDirectorMar 16Sale10.412,00020,82051,650Mar 16 04:55 PM
Shea Jacqueline ElizabethChief Operating OfficerMar 12Sale10.0616,881169,82355,417Mar 12 06:32 PM
Weiner David B.DirectorMar 09Sale9.603,50033,601843,552Mar 09 07:03 PM
Weiner David B.DirectorMar 08Sale9.183,50032,135835,385Mar 09 07:03 PM
BENITO SIMON XDirectorFeb 16Option Exercise3.562,0007,12053,650Feb 18 07:04 PM
BENITO SIMON XDirectorFeb 16Sale14.682,00029,36051,650Feb 18 07:04 PM
Kim Jong JosephChief Executive OfficerFeb 03Option Exercise4.5662,500285,0001,140,813Feb 03 07:14 PM
Kim Jong JosephChief Executive OfficerFeb 03Sale14.2462,500890,0001,078,313Feb 03 07:14 PM
Shea Jacqueline ElizabethChief Operating OfficerFeb 01Option Exercise3.6222,37681,00166,871Feb 03 07:12 PM
Kim Jong JosephChief Executive OfficerFeb 01Sale15.00100,0001,500,0001,078,313Feb 03 07:14 PM
Shea Jacqueline ElizabethChief Operating OfficerFeb 01Sale15.0528,336426,38338,535Feb 03 07:12 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 28Option Exercise3.6255,248199,99861,208Jan 29 07:03 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 28Sale12.0416,713201,22544,495Jan 29 07:03 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 27Option Exercise3.6222,37681,00134,296Jan 29 07:03 PM
Shea Jacqueline ElizabethChief Operating OfficerJan 27Sale12.0228,336340,4945,960Jan 29 07:03 PM